Neuroprotection of Retinal Ganglion Cells by Muller Glia: Investigation of the Role of the Wnt Signaling Pathway
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2008 - September 30, 2010
Grant ID
G2008029
Goals
These experiments will determine whether Wnt molecules can protect retinal ganglion cells from dying, will identify how Wnts promote survival, and will elucidate the role of Muller glia in glaucoma. The results of this study will provide new insights into glaucoma and may reveal novel directions towards developing preventive therapies.
Summary
This research will address several important questions: What causes retinal ganglion cells (RGCs) to sicken and die in glaucoma? Which genes and proteins are implicated in RGC demise? Can new methods be used to save RGCs and preserve vision? Molecules called Wnts promote the survival of various types of cells, and could potentially protect retinal ganglion cells. The scientists believe that protective Wnts normally increase in glaucoma, but the levels are not high enough to save RGCs. They will determine whether delivering extra Wnt molecules protects RGCs grown in the lab, and identify the genes and proteins involved. They will also test whether another cell type in the retina called Muller glia, known to secrete high levels of Wnt molecules, can help save RGCs from dying. Finally, they will examine donated glaucomatous eyes to determine whether Wnts are elevated.
Related Grants
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
National Glaucoma Research
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
National Glaucoma Research
Human Retinal Regeneration to Cure Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Karl Wahlin, PhD
Current Organization
University of California, San Diego
Human Retinal Regeneration to Cure Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Karl Wahlin, PhD
Current Organization
University of California, San Diego